Lupin recalls over 54,000 vials of anti-bacterial injection in US

09 Jun 2016 Evaluate

Lupin has recalled over 54,000 vials of anti-bacterial injection, Ceftriaxone, due to violation of current manufacturing norms. The ongoing voluntary recall is a class-III recall for the US and Puerto Rico markets.

The recall is being initiated by the company’s US arm Lupin Pharmaceuticals Inc covering 54,472 vials of Ceftriaxone for injection in various strengths. The company is also recalling 741.171 kg of Ceftriaxone Sodium (Sterile) active pharmaceutical ingredient as its API intermediates failed specifications.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin Share Price

2079.50 -33.45 (-1.58%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×